Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 12/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31679756 | 1.00 | PDE5A (0.71) | PDE5A | |
| SCHEMBL21682624 | 1.00 | PDE5A (0.71) | PDE5A | |
| SCHEMBL23723933 | 1.00 | PDE5A (0.71) | PDE5A | |
| Fumaric Acid SCHEMBL21682500 | 0.97 | PDE5A (0.66) | PDE5A | |
| Fumaric Acid SCHEMBL30052828 | 0.97 | PDE5A (0.66) | PDE5A | |
| Maleic Acid SCHEMBL30052992 | 0.97 | PDE5A (0.66) | PDE5A | |
| Maleic Acid SCHEMBL21682587 | 0.97 | PDE5A (0.66) | PDE5A | |
| Maleic Acid SCHEMBL21682588 | 0.97 | PDE5A (0.66) | PDE5A | |
| Fumaric Acid SCHEMBL21682499 | 0.97 | PDE5A (0.66) | PDE5A | |
| SCHEMBL31679749 | 0.95 | PDE5A (0.63) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4440549-B1 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS CONTAINING A NITRIC OXIDE-RELEASING PHOSPHODIESTERASE 5 INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | NICOX SA (FR) | 2025-11-12 | — | — | EP | claimed |
| EP-4233867-B1 | PDE5 INHIBITOR FOR USE IN THE TREATMENT OF ANTERIOR ISCHEMIC OPTIC NEUROPATHY | NICOX SA (FR) | 2025-09-03 | — | — | EP | claimed |
| US-20250017928-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS CONTAINING A NITRIC OXIDE-RELEASING PHOSPHODIESTERASE 5 INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | NICOX SA (FR) | 2025-01-16 | — | — | US | claimed |
| EP-4440549-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS CONTAINING A NITRIC OXIDE-RELEASING PHOSPHODIESTERASE 5 INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | Nicox SA (FR) | 2024-10-09 | — | — | EP | claimed |
| EP-4100014-B1 | COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION | NICOX SA (FR) | 2024-01-03 | — | — | EP | claimed |
| EP-4236952-A1 | NO-PDE5 INHIBITOR FOR USE IN TREATING DRY AGE-RELATED MACULAR DEGENERATION, GEOGRAPHIC ATROPHY AND GLAUCOMA-ASSOCIATED NEURODEGENERATION | Nicox S.A. (FR) | 2023-09-06 | — | — | EP | claimed |
| WO-2023161314-A1 | PDE5 INHIBITOR FOR USE IN THE TREATMENT OF ANTERIOR ISCHEMIC OPTIC NEUROPATHY | NICOX SA (FR) | 2023-08-31 | — | — | WO | claimed |
| WO-2023099638-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS CONTAINING A NITRIC OXIDE-RELEASING PHOSPHODIESTERASE 5 INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | NICOX SA (FR) | 2023-06-08 | — | — | WO | claimed |
| WO-2022090379-A1 | NO-PDE5 INHIBITOR FOR USE IN TREATING DRY AGE-RELATED MACULAR DEGENERATION, GEOGRAPHIC ATROPHY AND GLAUCOMA-ASSOCIATED NEURODEGENERATION | NICOX S.A. (FR) | 2022-05-05 | — | — | WO | claimed |
| EP-4233867-B1 | PDE5 INHIBITOR FOR USE IN THE TREATMENT OF ANTERIOR ISCHEMIC OPTIC NEUROPATHY | NICOX SA (FR) | 2025-09-03 | — | — | EP | disclosed |
| EP-4440549-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS CONTAINING A NITRIC OXIDE-RELEASING PHOSPHODIESTERASE 5 INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | Nicox SA (FR) | 2024-10-09 | — | — | EP | disclosed |
| EP-4100014-B1 | COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION | NICOX SA (FR) | 2024-01-03 | — | — | EP | disclosed |
| EP-4236952-A1 | NO-PDE5 INHIBITOR FOR USE IN TREATING DRY AGE-RELATED MACULAR DEGENERATION, GEOGRAPHIC ATROPHY AND GLAUCOMA-ASSOCIATED NEURODEGENERATION | Nicox S.A. (FR) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023161314-A1 | PDE5 INHIBITOR FOR USE IN THE TREATMENT OF ANTERIOR ISCHEMIC OPTIC NEUROPATHY | NICOX SA (FR) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023161314-A1 | PDE5 INHIBITOR FOR USE IN THE TREATMENT OF ANTERIOR ISCHEMIC OPTIC NEUROPATHY | NICOX SA (FR) | 2023-08-31 | — | — | WO | disclosed |
| EP-4233867-A1 | PDE5 INHIBITOR FOR USE IN THE TREATMENT OF ANTERIOR ISCHEMIC OPTIC NEUROPATHY | Nicox SA (FR) | 2023-08-30 | — | — | EP | disclosed |
| WO-2023099638-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS CONTAINING A NITRIC OXIDE-RELEASING PHOSPHODIESTERASE 5 INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | NICOX SA (FR) | 2023-06-08 | — | — | WO | disclosed |
| US-20230069076-A1 | COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION | NICOX S.A. (FR) | 2023-03-02 | — | — | US | disclosed |
| EP-4100014-A1 | COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION | Nicox S.A. (FR) | 2022-12-14 | — | — | EP | disclosed |
| WO-2022090379-A1 | NO-PDE5 INHIBITOR FOR USE IN TREATING DRY AGE-RELATED MACULAR DEGENERATION, GEOGRAPHIC ATROPHY AND GLAUCOMA-ASSOCIATED NEURODEGENERATION | NICOX S.A. (FR) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230069076-A1 | COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION | PTGIS, PDE5A, PDE3A | PDE5A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.